Mylan Pharmaceuticals
Trial Pipeline
Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential
NCT06672016
Single-Dose Fed Bioequivalence Study of Nisoldipine Extended-Release Tablets (40 mg; Mylan) and Sular® Extended-Release Tablets (40 mg; First Horizon) in Healthy Volunteers
NCT00979537
Fed Study of Balsalazide Disodium Capsules 750 mg and Colazal® Capsules 750 mg
NCT00649480
Food Study of Paroxetine Hydrochloride Tablets 40 mg and Paxil® Tablets 40 mg
NCT00650403
Fasting Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg and Benicar HCT® Tablets 40 mg/25 mg
NCT01020214
Fed Study of Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg and Corzide® Tablets 80 mg/5 mg
NCT00648297
Fasting Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg
NCT00647673
Fed Study of Olmesartan Medoxomil Tablets 40 mg and Benicar® Tablets 40 mg
NCT00648219
Fasting Study of Olmesartan Medoxomil Tablets 40 mg and Benicar® Tablets 40 mg
NCT00649623
Fasting Study of Topiramate Sprinkle Capsules 25 mg and Topamax® Sprinkle Capsules 25 mg
NCT00649740
Food Study of Letrozole Tablets 2.5 mg and Femara® Tablets 2.5 mg
NCT00648154
Fed Study of Topiramate Sprinkle Capsules 25 mg and Topamax® Sprinkle Capsules 25 mg
NCT00648934
Fasting Study of Letrozole Tablets 2.5 mg and Femara® Tablets 2.5 mg
NCT00648063
Fasting Study of Ciprofloxacin Extended-Release Tablets 1000 mg and Cipro® XR Tablets 1000 mg
NCT00649662
Fed Study of Valacyclovir Hydrochloride Tablets 1000 mg and Valtrex® Tablets 1000 mg
NCT00650494
Food Study of Glipizide and Metformin HCl Tablets 5 mg/500 mg to Metaglip® Tablets 5 mg/500 mg
NCT00648505
Food Study of Valacyclovir Hydrochloride Tablets 1000 mg to Valtrex® Tablets 1000 mg
NCT00649870
Fasting Study of Azithromycin Tablets 600 mg to Zithromax® Tablets 600 mg
NCT00650273
Fasting Study of Clopidogrel Bisulfate Tablets 75 mg to Plavix® Tablets 75 mg
NCT00648947
Fasting Study of Sumatriptan Succinate Tablets 100 mg to Imitrex® Tablets 100 mg
NCT00648466
Food Study of Glimepiride Tablets 1 mg to Amaryl® Tablets 1 mg
NCT00650533
Food Study of Sumatriptan Succinate Tablets 100 mg to Imitrex® Tablets 100 mg
NCT00650247
Fed Study of Carvedilol Tablets 12.5 mg to Coreg® Tablets 12.5 mg
NCT00648622
Fasting Study of Cilostazol Tablets 100 mg and Pletal® Tablets 100 mg
NCT00648388
Fasting BE Study of Metformin Hydrochloride ER Tablets 500 mg and Glucophage® XR Tablets 500 mg
NCT00650234
Fasting Study of Fexofenadine Tablets 180 mg and Allegra® Tablets 180 mg
NCT00649376
Food Study of Sertraline Hydrochloride Tablets 100 mg and Zoloft® Tablets 100 mg
NCT00648856
Fed Study of Metoprolol Tartrate Tablets 100 mg and Lopressor® 100 mg
NCT00649116
Fed Study of Metoprolol Tartrate Tablets 25 mg and Lopressor® 50 mg
NCT00648271
Fasting Study of Oxybutynin Chloride Extended-release Tablets 5 mg and Ditropan XL® Tablets 5 mg
NCT00650481
Fed Study of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Lotensin HCT® Tablets 20 mg/25 mg
NCT00649038
Fasting Study of Cetirizine HCl Tablets 10 mg and Zyrtec® Tablets 10 mg
NCT00650065
Food Study of Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg and Macrobid® Capsules 100 mg
NCT00649285
Food Study Metformin Hydrochloride ER Tablets 500 mg and Glucophage® XR 500 mg
NCT00648492
Fasting Study of Midodrine HCl Tablets 5 mg and ProAmatine® Tablets 5 mg
NCT00650364
Fed Study of Oxybutynin Chloride Extended-release Tablets 10 mg and Ditropan XL® Tablets 10 mg
NCT00649727
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 35 |
| Phase 3 | 1 |
Therapeutic Areas
What the Pipeline for Mylan Pharmaceuticals Shows
According to the ClinicalTrials.gov registry, Mylan Pharmaceuticals is linked to 36 US clinical trials across every stage of research activity. Of those, 1 studies are currently recruiting — about 3% of the sponsor's indexed portfolio — and 35 are already marked complete, representing roughly 97% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Mylan Pharmaceuticals reports 1 late-stage studies (Phase 3 and Phase 4 combined) and 35 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Mylan Pharmaceuticals is Healthy with 35 linked trials, and 1 other condition area appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.